世界のムーコル症市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV03859)
◆英語タイトル:Global Mucormycosis Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV03859
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2023年版があります。お問い合わせください。)
◆ページ数:92
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥538,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥807,300見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,076,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートはムーコル症の世界市場について調査・分析した資料です。種類別(手術、抗真菌薬、アムホテリシンB療法)の市場規模、用途別(病院・診療所、医療機関、研究機関)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別ムーコル症の競争状況、市場シェア
・世界のムーコル症市場:種類別市場規模 2015年-2020年(手術、抗真菌薬、アムホテリシンB療法)
・世界のムーコル症市場:種類別市場規模予測 2021年-2026年(手術、抗真菌薬、アムホテリシンB療法)
・世界のムーコル症市場:用途別市場規模 2015年-2020年(病院・診療所、医療機関、研究機関)
・世界のムーコル症市場:用途別市場規模予測 2021年-2026年(病院・診療所、医療機関、研究機関)
・北米のムーコル症市場分析:米国、カナダ
・ヨーロッパのムーコル症市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのムーコル症市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のムーコル症市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのムーコル症市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Abbott Laboratories、Biocon、Cadila Pharmaceuticals、Novartis、Merck、Roche、Bristol Myers Squibb、Pfizer
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Mucormycosis is any fungal infection caused by fungi in the order Mucorales. Generally, species in the Mucor, Rhizopus, Absidia, and Cunninghamella genera are most often implicated. The disease is often characterized by hyphae growing in and around blood vessels and can be potentially life-threatening in diabetic or severely immunocompromised individuals.
If mucormycosis is suspected, amphotericin B therapy should be immediately administered due to the rapid spread and high mortality rate of the disease. Amphotericin B is usually administered for an additional 4–6 weeks after initial therapy begins to ensure eradication of the infection. After administration of either amphotericin B or posaconazole, surgical removal of the “fungus ball” is indicated. The disease must be monitored carefully for any signs of reemergence.

Market Analysis and Insights: Global Mucormycosis Market
The global Mucormycosis market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Mucormycosis Scope and Market Size
Mucormycosis market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Mucormycosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Abbott Laboratories
Biocon
Cadila Pharmaceuticals
Novartis
Merck
Roche
Bristol Myers Squibb
Pfizer

Market segment by Type, the product can be split into
Surgery
Antifungal Drugs
Amphotericin B Therapy
Market segment by Application, split into
Hospitals & Clinics
Medical Institutes
Research Organization

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Mucormycosis Revenue
1.4 Market by Type
1.4.1 Global Mucormycosis Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Surgery
1.4.3 Antifungal Drugs
1.4.4 Amphotericin B Therapy
1.5 Market by Application
1.5.1 Global Mucormycosis Market Share by Application: 2020 VS 2026
1.5.2 Hospitals & Clinics
1.5.3 Medical Institutes
1.5.4 Research Organization
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Mucormycosis Market Perspective (2015-2026)
2.2 Global Mucormycosis Growth Trends by Regions
2.2.1 Mucormycosis Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Mucormycosis Historic Market Share by Regions (2015-2020)
2.2.3 Mucormycosis Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Mucormycosis Market Growth Strategy
2.3.6 Primary Interviews with Key Mucormycosis Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Mucormycosis Players by Market Size
3.1.1 Global Top Mucormycosis Players by Revenue (2015-2020)
3.1.2 Global Mucormycosis Revenue Market Share by Players (2015-2020)
3.1.3 Global Mucormycosis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Mucormycosis Market Concentration Ratio
3.2.1 Global Mucormycosis Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Mucormycosis Revenue in 2019
3.3 Mucormycosis Key Players Head office and Area Served
3.4 Key Players Mucormycosis Product Solution and Service
3.5 Date of Enter into Mucormycosis Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Mucormycosis Historic Market Size by Type (2015-2020)
4.2 Global Mucormycosis Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Mucormycosis Market Size by Application (2015-2020)
5.2 Global Mucormycosis Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Mucormycosis Market Size (2015-2020)
6.2 Mucormycosis Key Players in North America (2019-2020)
6.3 North America Mucormycosis Market Size by Type (2015-2020)
6.4 North America Mucormycosis Market Size by Application (2015-2020)

7 Europe
7.1 Europe Mucormycosis Market Size (2015-2020)
7.2 Mucormycosis Key Players in Europe (2019-2020)
7.3 Europe Mucormycosis Market Size by Type (2015-2020)
7.4 Europe Mucormycosis Market Size by Application (2015-2020)

8 China
8.1 China Mucormycosis Market Size (2015-2020)
8.2 Mucormycosis Key Players in China (2019-2020)
8.3 China Mucormycosis Market Size by Type (2015-2020)
8.4 China Mucormycosis Market Size by Application (2015-2020)

9 Japan
9.1 Japan Mucormycosis Market Size (2015-2020)
9.2 Mucormycosis Key Players in Japan (2019-2020)
9.3 Japan Mucormycosis Market Size by Type (2015-2020)
9.4 Japan Mucormycosis Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Mucormycosis Market Size (2015-2020)
10.2 Mucormycosis Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Mucormycosis Market Size by Type (2015-2020)
10.4 Southeast Asia Mucormycosis Market Size by Application (2015-2020)

11 India
11.1 India Mucormycosis Market Size (2015-2020)
11.2 Mucormycosis Key Players in India (2019-2020)
11.3 India Mucormycosis Market Size by Type (2015-2020)
11.4 India Mucormycosis Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Mucormycosis Market Size (2015-2020)
12.2 Mucormycosis Key Players in Central & South America (2019-2020)
12.3 Central & South America Mucormycosis Market Size by Type (2015-2020)
12.4 Central & South America Mucormycosis Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Abbott Laboratories
13.1.1 Abbott Laboratories Company Details
13.1.2 Abbott Laboratories Business Overview
13.1.3 Abbott Laboratories Mucormycosis Introduction
13.1.4 Abbott Laboratories Revenue in Mucormycosis Business (2015-2020))
13.1.5 Abbott Laboratories Recent Development
13.2 Biocon
13.2.1 Biocon Company Details
13.2.2 Biocon Business Overview
13.2.3 Biocon Mucormycosis Introduction
13.2.4 Biocon Revenue in Mucormycosis Business (2015-2020)
13.2.5 Biocon Recent Development
13.3 Cadila Pharmaceuticals
13.3.1 Cadila Pharmaceuticals Company Details
13.3.2 Cadila Pharmaceuticals Business Overview
13.3.3 Cadila Pharmaceuticals Mucormycosis Introduction
13.3.4 Cadila Pharmaceuticals Revenue in Mucormycosis Business (2015-2020)
13.3.5 Cadila Pharmaceuticals Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview
13.4.3 Novartis Mucormycosis Introduction
13.4.4 Novartis Revenue in Mucormycosis Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Mucormycosis Introduction
13.5.4 Merck Revenue in Mucormycosis Business (2015-2020)
13.5.5 Merck Recent Development
13.6 Roche
13.6.1 Roche Company Details
13.6.2 Roche Business Overview
13.6.3 Roche Mucormycosis Introduction
13.6.4 Roche Revenue in Mucormycosis Business (2015-2020)
13.6.5 Roche Recent Development
13.7 Bristol Myers Squibb
13.7.1 Bristol Myers Squibb Company Details
13.7.2 Bristol Myers Squibb Business Overview
13.7.3 Bristol Myers Squibb Mucormycosis Introduction
13.7.4 Bristol Myers Squibb Revenue in Mucormycosis Business (2015-2020)
13.7.5 Bristol Myers Squibb Recent Development
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview
13.8.3 Pfizer Mucormycosis Introduction
13.8.4 Pfizer Revenue in Mucormycosis Business (2015-2020)
13.8.5 Pfizer Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Abbott Laboratories、Biocon、Cadila Pharmaceuticals、Novartis、Merck、Roche、Bristol Myers Squibb、Pfizer

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のムーコル症市場2026:インサイト・予測(Global Mucormycosis Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。